The Promise and Challenge of GLP-1 Medications: Ensuring ROI in Obesity Care
Pricy GLP-1 medications are here to stay — let's focus on turning their potential into lasting, meaningful impact.
Why Medicare Should Treat Obesity as a Disease
Medicare is failing its beneficiaries by not treating obesity as a disease. Just like people with high blood pressure often need to take medications to avoid disease-related complications, people with obesity need access to all appropriate, evidence-based therapies to combat the disease.
presented by
Survey on the Healthcare Financial Landscape Offers a Roadmap for Stakeholders
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.